In case you didn’t see the real reason for the drop in the lengthy thread…
Abiomed added $5 million to its full fiscal 2016 revenue guidance, now between $305 million and $315 million. It also lifted its operating-margin guidance by a percentage point to a range of 15% to 17%. It did not provide EPS guidance.
While the guidance was in line with consensus, it implied a considerable slowdown — 24% to 28% growth in the second half of the year vs. 49% in the first, according to Jefferies analyst Raj Denhoy’s calculations. Evidently Abiomed had lifted investor hopes on its Aug. 11 analyst day when it targeted 40% annual growth over the next five years, a point raised by a William Blair analyst during the conference call to discuss the results.
“It’s not a forecast, but it’s our goal, and now you can understand why we are investing in manufacturing and distribution and research,” answered CEO Michael Minogue.